The evidence keeps on mounting up
Even though it is unconfirmed and speculation on my part.......it makes sense
Faslodex is out of patent
Faslodex generated more than a billion US$ for AstraZeneca in 2018
Faslodex's revenue is diminishing as more and more generics come into the market
Jeffries have indicated possible revenues streams could be worth in excess of 2-3 billion US dollars
AstraZeneca formulation would have generated a far greater revenue if it could target cancer more effectively
So.......
Starpharma has been developing novel formulations based on its drug delivery platform which currently in human clinical studies are showing great efficacy and largely less side effects
Starpharma has agreement in place with AstraZeneca to jointly develop Azd0466
Starpharma has agreement in place to conduct pre-clinical novel formulation to improve an AstraZeneca drug which is now out of patent
Put two and two together and you have four.........my money is on Dep Faslodex
We could have an answer before June 2020
And a further 7.5 million US$ in the bank plus milestones plus royalties if AstraZeneca take up option to develop drug
Another snippet below
Bye-bye, blockbuster? AstraZeneca's Faslodex gets U.S. generic on heels of record sales year
by
Kyle Blankenship |
May 31, 2019 11:10am
AstraZeneca could be saying goodbye to an oncology blockbuster after Novartis' Sandoz launched a Faslodex generic this week. (AstraZeneca)
ShareFacebookTwitterLinkedInEmailPrint
AstraZeneca rightly celebrated its longtime breast cancer therapy Faslodex reaching blockbuster status in 2018 for the first time. But one year later, with a first-ever Faslodex generic hitting the market stateside, what can AstraZeneca expect from the drug’s future?
On Thursday, Novartis’ Sandoz unit launched its generic version of Faslodex (fulvestrant) as a solo or combination therapy for HR-positive metastatic breast cancer, threatening AstraZeneca’s $541 million in annual U.S. sales as of March 2019. The fulvestrant generic is part of Sandoz’s renewed push into the oncology generic market, Novartis said in a release.
“Fulvestrant is an important treatment option for women with advanced breast cancer and we will work to help those in the U.S. who need this critical therapy have access to it at an affordable price,” Sandoz President Carol Lynch said.
The bad news for AstraZeneca followed a series of wins for the nearly 20-year-old Faslodex after positive phase 3 trial data in late 2017 showed the drug’s promise as a solo treatment for breast cancer in post-menopausal women who haven’t undergone endocrine therapy and as a combo therapy with CDK 4/6 inhibitors. In fact, by the end of 2018, Faslodex had been approved as a backbone treatment for most of the CDK 4/6 inhibitor class treating HR-positive, HER2-negative breast cancer, the company said.
RELATED: Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali
Those wins translated into all-time-high sales for Faslodex, with more than $1 billion in global revenue in 2018 and $537 million in U.S. sales. Those global figures were an impressive leap from $941 million in 2017 and an even more impressive leap from $830 million in 2016.
The launch of Novartis’ generic followed a court settlement in July 2016 putting off U.S. generic competition until March 2019, according to company filings. AstraZeneca filed a separate injunction in June 2018 to stop the generic’s launch in France, which was rejected by a French court.
(20min delay)